The long-term risk of tuberculosis among individuals with Xpert Ultra "trace" screening results: a longitudinal follow-up study

Authors: Joowhan Sung, MD[1,2], Mariam Nantale, MPH[2], Annet Nalutaaya, MS[2], Patrick Biché, MPH[3], James Mukiibi[2], Joab Akampurira[2], Rogers Kiyonga[2], Francis Kayondo[2], Michael Mukiibi[2], Caitlin Visek, MD[1], Caleb E Kamoga[2], Prof David W Dowdy, MD[2,3], Achilles Katamba, MBChB[2,4], Emily A Kendall, MD[1.2.3]

[1]Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD, USA

[2]Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda

[3]Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD, USA

[4]Makerere University College of Health Science, Department of Internal Medicine, Clinical Epidemiology and Biostatistics Unit, Kampala, Uganda

Correspondence: Joowhan Sung, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. email: jsung21@jhmi.edu

Summary

Background: Systematic screening for tuberculosis using Xpert Ultra generates "trace" results of
uncertain significance. Additional microbiological testing in this context is often negative, but untreated
individuals might still progress to culture-positive disease. We aimed to estimate the two-year risk of
tuberculosis among screening participants with trace-positive sputum.

Methods: We screened 31,505 people for tuberculosis in Uganda using sputum Xpert Ultra as an initial
test, through event-based and door-to-door screening. We enrolled participants with trace-positive
sputum (PWTS) and Ultra-negative controls into a prospective cohort, and Ultra-positive (>trace)
controls for cross-sectional comparison. All participants underwent extensive initial evaluation, and
untreated PWTS and negative controls were followed with re-testing for up to 24 months. We estimated
cumulative hazards of tuberculosis among PWTS versus negative controls, using two definitions of
tuberculosis: one incorporating clinician judgment (primary) and one based strictly on microbiological
results (secondary). We then compared hazards between subgroups of PWTS.

Findings: Of 128 PWTS, 79 (62%) were male and 19 (15%) were HIV-positive. Forty-five (35%) PWTS
were recommended for treatment upon enrollment, eight were lost to follow-up within three months, and
75 followed for median 706 (interquartile range 344-714) days, of whom 19 were recommended for
treatment during follow-up. The cumulative hazard of tuberculosis among PWTS not treated at baseline
was 0.24 (95% confidence interval: 0.15-0.40) at one year and 0.33 (0.21-0.54) at two years, versus
0.03 (0.01-0.10) at two years for negative controls. Hazards were similar for microbiologically defined
tuberculosis (0.36 [0.22-0.58] at 2 years). Tuberculosis diagnosis during follow-up was strongly
associated with abnormal baseline chest X-ray (hazard ratio 14.6 [3.3-63.8]) but not with baseline
symptoms.

Interpretation: Individuals with trace-positive sputum during screening have a substantial two-year risk
of tuberculosis, even when extensive initial evaluations do not confirm disease. Treatment should be
considered for most screening participants with trace-positive sputum and abnormal chest imaging.

Funding: National Institutes of Health

Research in context

Evidence before this study

Recent advances in tuberculosis research have shifted the disease framework from a binary
classification of latent versus active tuberculosis to a continuum of disease states. They have also led
to a better understanding of the dynamic disease course of early tuberculosis, which can either
progress to culture-positive disease or regress spontaneously over time. "Trace" results from Xpert
MTB/RIF Ultra ("Ultra") are sometimes perceived as false positives in individuals who subsequently test
negative on additional diagnostic assays. However, some of these individuals may have early
tuberculosis that falls below the detection threshold of existing diagnostic tests and could progress to
microbiologically detectable disease over time. In screening contexts, trace-positive Ultra results
constitute up to half of all positive results, and it is critical to understand how to interpret this result from
screening participants, particularly among individuals without further evidence of tuberculosis on
additional testing. To investigate this, we searched PubMed for studies published in English from
inception to up to February 7, 2025, using the terms "tuberculosis" AND ("Xpert" OR "Xpert Ultra" OR
"Ultra") AND "Trace" and also reviewed the reference lists of relevant search results. In two prevalence
surveys that each used a combination of symptom and chest X-ray as the screening test with Ultra as a
confirmatory test, the proportion with positive cultures among those with trace-positive sputum ranged
from 20% and 38%. In a study conducted in Uganda where Ultra was used as an initial screening test,
only 14% of individuals with a trace-positive result had positive sputum cultures. However, prior studies
were limited to a one-time evaluation of individuals following a trace result. None longitudinally followed
these individuals after a negative initial work-up to assess their long-term risk of tuberculosis and its
predictors, and appropriate management strategy for such individuals remains unknown.

Added value of this study

In this study, individuals with Ultra trace-positive screening results who were not started on treatment
after extensive diagnostic testing were followed for up to two years with repeated testing. The 2-year
cumulative hazard of tuberculosis disease was substantial at 0.33 (95% confidence interval 0.21-0.54),
compared to 0.03 (0.01-0.10) among individuals with Ultra-negative screening results. Those who had
a normal chest X-ray at enrollment were at significantly lower risk of developing tuberculosis. Two-year
tuberculosis risk was similar between those who reported symptoms at the time of enrollment and those
who did not.

Implications of all the available evidence

The high two-year risk of tuberculosis observed among people with trace results in this study, even

when Ultra was used without any prior screening step, support provision of treatment for tuberculosis

disease to most individuals who receive trace results during tuberculosis screening interventions.

These results also demonstrate that X-ray could be a useful tool to guide treatment decision-making for

individuals with trace-positive sputum.

Introduction

Despite being a curable disease, tuberculosis continues to be the leading single-agent infectious cause of death worldwide, accounting for 1.25 million deaths in 2023.[1] It is estimated that about 25% of individuals who develop tuberculosis are never diagnosed and started on treatment [1]. Detecting tuberculosis at early stages through effective diagnostic strategies could reduce transmission and prevent severe outcomes.

Tuberculosis programs are increasingly conducting community-based tuberculosis screening,[2] and during such screening efforts, Xpert MTB/RIF Ultra ("Ultra"; Cepheid), a molecular diagnostic tool for tuberculosis, is widely used as a confirmatory test for individuals with tuberculosis symptoms and/or abnormal chest X-rays. In screening contexts, a large proportion of positive Ultra results are in the "trace" category.[3-5] Trace results, which represent the lowest level of *M. tuberculosis (Mtb)* DNA detection, are reported when the Ultra assay detects one of its multicopy amplification targets (*IS1660* or *IS1810*) but not its single-copy *rpoB* gene target.[6] Studies that have used Ultra as an initial or confirmatory test during general-population screening in high-burden settings have reported that 24% to 46% of positive results are trace-positive.[3-5, 7]

Due to lower tuberculosis prevalence among general populations than compared to symptomatic patients tested at health facilities, the positive predictive value of a trace result could be lower in screening contexts, but it is uncertain what proportion of trace results reflect underlying tuberculosis disease. We previously reported on systematic screening for tuberculosis that we conducted in Uganda, using Ultra as an initial test regardless of symptoms, with detailed baseline evaluation of participants who received trace results.[5] Among the first 92 such participants, only 22 (24%) had microbiologically confirmed tuberculosis, with just 13 (14%) having a positive culture. However, tuberculosis has a dynamic and varied disease course, with progression and regression of bacterial burden occurring across different states of infection. [8-10] We hypothesized that some individuals with trace-positive sputum who are otherwise microbiologically negative may have early (or otherwise minimal-burden) disease that could progress over time, such that they could potentially benefit from preventive or empirical treatment. No existing studies have evaluated the long-term risk of tuberculosis among individuals with trace-positive sputum who otherwise do not have current evidence for tuberculosis. Therefore, within the same cohort after additional enrollment, we aimed to estimate the two-year risk of tuberculosis disease among participants with trace-positive screening results who had completed detailed evaluations for tuberculosis without definite evidence of tuberculosis.

Methods

Symptom-Neutral Tuberculosis Screening and Participant Recruitment

We conducted Ultra-based systematic screening for tuberculosis in Kampala, Uganda, from February 2021 to April 2024, enrolling individuals with trace-positive results as well as Ultra-positive and Ultra-negative controls. Procedures for recruitment, described previously,[5] were continued through April 2024 and are detailed in appendix (**p 3**). Briefly, participants for tuberculosis screening were recruited primarily through community-based screening events and door-to-door screening and to a lesser extent through contact investigations. Ultra sputum testing was offered to any individuals aged ≥15 years who were not on active tuberculosis treatment, regardless of their symptoms. Upon receiving the Ultra results from the study's screening activities, we recruited all participants with trace-positive screening results, as well as age- and sex-matched participants with negative screening results ("negative controls") and consecutive participants with positive (>trace) screening results ("positive controls"), for further diagnostic evaluation (**appendix p 4)**. To enhance our sample size, we also enrolled people who were found to have trace-positive sputum during community-based, symptom-agnostic Ultra testing that was offered in high-risk areas of Kampala during a national screening campaign.[11] Tuberculosis screening continued until 128 participants with trace-positive sputum were enrolled (sample size explained in **appendix p 5**).

Evaluation and Follow-Up of Study Participants

Upon enrollment, participants with trace-positive sputum (PWTS) received extensive diagnostic testing, including symptom survey (**appendix pp 7-9**), repeat sputum Ultra, two sets of sputum liquid and solid mycobacterial cultures, HIV testing (using a serial rapid testing algorithm,[12] if not known positive), chest X-ray (CXR), and chest computed tomography (CT). Participants with HIV also received urine lipoarabinomannan (LAM) testing (Determine TB LAM; Abbott). Participants screened after June 2021 were additionally surveyed about tuberculosis symptoms at the time of screening (**appendix p 9**). A panel of experienced Ugandan pulmonologists and radiologists ("consultants") reviewed all available new results — including clinical risk factors, symptoms, laboratory results, and chest imaging — for PWTS and for negative controls with abnormal findings, and made recommendations for additional diagnostic testing and/or initiation of treatment. PWTS who were not recommended for tuberculosis treatment or declined treatment were followed with scheduled re-evaluations at 1, 3, 6, 12, and 24 months (**Figure 1**), in addition to unscheduled re-evaluations as needed. At each scheduled follow-up visit, participants were assessed for symptoms and asked to provide expectorated sputum for repeat testing by Ultra. Sputum cultures and chest X-rays were repeated at the 3- and 12-month follow-up

visits, with additional cultures at 6 and 24 months added partway through the study (in November 2023).

Both negative and positive control participants underwent the same diagnostic evaluations at baseline.

Negative control participants not recommended for treatment were followed for up to two years, with

symptom assessment at 6 months and repeat sputum testing at 12 and 24 months, except for one

negative control participant with a trace result on repeat Ultra testing who received frequent follow-up,

as offered to PWTS. Positive control participants were referred for treatment initiation.

Interpretation of Chest Imaging by Radiologists and CAD Software

Chest X-ray and CT images of study participants were reviewed by two independent radiologists, with a

third radiologist reviewing images if initial readings were discrepant. The radiologists, blinded to clinical

information, rated the consistency with current tuberculosis and (separately) with prior tuberculosis on

four-point scales. These scores were averaged across all radiologists for reporting (**Appendix p 10**). In

addition, all baseline chest X-rays were retrospectively analyzed using CAD software (qXR v4, Qure.ai,

India); CAD results were unavailable during treatment decision-making.

Statistical Analysis

Our primary analysis defined tuberculosis based on treatment recommendation (**appendix p 11**). Under

this definition, all participants for whom consultants recommended treatment or an external clinician

prescribed treatment were counted as having tuberculosis, including those diagnosed clinically.

Participants with positive microbiological results that clinicians or consultants interpreted as false-

positive were considered not to have tuberculosis. In secondary analyses, we defined tuberculosis

based on microbiological positivity, specifically as having a positive sputum Ultra (required to be higher

than trace to diagnose based on Ultra alone), a positive sputum culture for *M. tuberculosis* complex, or

(among people with HIV) a positive urine LAM. For survival analyses using microbiological positivity to

define tuberculosis outcomes, we censored participants who initiated treatment without microbiological

confirmation.

We first estimated the cumulative proportion of all PWTS who were recommended for treatment over

the course of the study, with a corresponding 95% confidence interval (CI) using the Wilson score

method. Participants lost to follow-up before three months were excluded from this analysis.

Then, we used survival analysis to evaluate the risk of tuberculosis diagnosis during follow-up among

those not diagnosed at baseline, comparing PWTS to negative controls. Participants were classified as

having tuberculosis at baseline if their diagnosis was based on the enrollment evaluation, including

positive baseline cultures that resulted weeks later. We estimated the cumulative cause-specific

hazards of developing tuberculosis among PWTS versus negative controls using the Nelson-Aalen

estimator[13] (**appendix p 12**). We then estimated hazards ratios and corresponding 95% confidence

intervals, comparing the two groups, using a Cox proportional hazards model. We performed this

analysis for both definitions of tuberculosis, using the corresponding definition of tuberculosis to also

define the cohort without tuberculosis at baseline. A sensitivity analysis repeated the same analyses

using only matched pairs (**appendix p 4**).

Using similar methods, we estimated the cumulative hazards of tuberculosis diagnosis during follow-up

among subgroups of PWTS with different baseline characteristics, and calculated hazard ratios for

baseline risk factors, including male sex, HIV infection, positive symptom status (based on a four-

symptom assessment), and history of prior tuberculosis treatment. We additionally estimated hazard

ratios comparing those with abnormal versus normal baseline chest imaging by each of several

definitions, namely (a) CXR read by radiologists as having any abnormalities, (b) CXR read as

suggestive of tuberculosis, (c) CXR with qXR tuberculosis score ["CAD score"] ≥0.2, (d) CXR with CAD

score ≥0.5, and (e) CT read as suggestive of tuberculosis. All comparisons between subsets of PWTS

were performed for each of two definitions of tuberculosis in parallel, and those with missing data for a

given risk factor were excluded.

Finally, we compared baseline demographic, clinical, and radiographic characteristics among the

following five groups of participants: 1) positive controls, 2) PWTS recommended for treatment at

baseline ("Trace, TB at baseline"), 3) PWTS recommended for treatment during follow-up ("Trace, TB

during follow-up"), 4) PWTS not recommended for treatment and followed for at least three months

("Trace, no TB"), and 5) negative controls. The CAD scores of baseline CXRs were compared between

five groups using Kruskall-Wallis tests followed by Dunn tests with Bonferroni correction.[14] We also

estimated the area under the curve (AUC) for the CAD score at baseline in diagnosing tuberculosis (at

baseline or during follow-up, using two definitions) among PWTS who were either diagnosed or

followed for ≥three months. This analysis was conducted after all participants had sufficient time to

complete twelve months of follow-up (**appendix p 13**). Statistical significance was determined as a two-

sided alpha <0.05. Analyses were performed using Stata version 16.1 and R version 4.3.2.

Ethics Considerations

Informed consent (or adolescent assent with parental consent) was obtained from all study participants.

The Institutional Review Boards of the Johns Hopkins University School of Medicine (IRB00269370)

and the Makerere University School of Public Health (Protocol 901) approved the study.

Results

A total of 31,505 individuals aged ≥15 years consented to tuberculosis screening, including 16,568 recruited through event-based screening, 14,782 through door-to-door screening, and 155 through contact investigation. Of these, 31,321 (>99%) successfully provided sputum samples, and 31,150 had valid Ultra results. Among valid results, 297 (1.0% of 31,150) were positive, including 125 (42%) trace-positives. We recruited 109 of these 125 (87%) individuals with trace screening results and additionally recruited 19 participants who were found to have trace-positive sputum during a national screening campaign[11] to enroll a total of 128 PWTS (**Figure 2**). We also enrolled 139 matched Ultra-negative controls and 110 (76% of 144 eligible) positive controls.

Among 128 PWTS, the median age was 33 (interquartile range [IQR]: 24-39), 62% (79/128) were male, 15% (19/128) had HIV infection, 46% (42/91 who were assessed) reported any cough at screening. (**Table 1**). Of 128 PWTS, 45 (35%) were recommended tuberculosis treatment based on additional testing performed at baseline, including 36 participants with microbiological confirmation and 27 with positive culture **(appendix pp 14-15)**. Of 45 PWTS recommended treatment at baseline, 34 had abnormal CXR, 41 had abnormal CT, and one did not complete imaging studies. Eight PWTS not recommended treatment were lost to follow-up before three months.

The cohort analyzed for tuberculosis diagnosis during follow-up consisted of 75 PWTS with no loss to follow-up before 3 months. They were followed for a median of 706 days (IQR 344–714), during which 19 (25% of 75) were recommended for tuberculosis treatment during follow-up, including 15 with microbiological confirmation (and 4 with microbiologically unconfirmed diagnoses [**appendix pp 16-17**], who were thus censored from the secondary analysis using a microbiologically-defined outcome). Therefore, when we considered diagnosis cumulatively from enrollment among all 120 PWTS with sufficient follow-up data for evaluation, 64 (53%, 95% CI 44-62%) were recommended for tuberculosis treatment either at baseline or during follow-up. Three deaths occurred among study participants, including one PWTS (**appendix p 13**) .

Among PWTS not diagnosed with tuberculosis through baseline evaluation, the cumulative cause-specific hazard of tuberculosis diagnosis during follow-up was 0.24 (95% CI 0.15-0.40) at one year and 0.33 (95% CI 0.21-0.54) at two years when estimated based on treatment recommendation. Corresponding cumulative hazards based on microbiological positivity were 0.26 (95% CI 0.16-0.42) at one year and 0.36 (95% CI 0.22-0.58) at two years. The two-year cumulative hazard among Ultra-negative controls was 0.03 (0.01-0.10) based on treatment recommendation, or 0.02 (0.01-0.10) based on microbiological positivity (**Figure 3 a-b**). Results restricted to matched pairs were similar (**appendix p 18**).

Among PWTS not diagnosed at baseline, tuberculosis diagnosis during follow-up was strongly

associated with abnormal baseline CXR (HR 14.6 [95% CI 3.3-63.8, p=0.0004] as interpreted by

human readers, **Figure 3 c-d**) but not with baseline cough (HR 1.2 95% CI 0.4-3.1, p=0.73) (**appendix**

p 19). Sex, HIV status, and history of prior tuberculosis had elevated hazard ratios (>1) for tuberculosis

diagnosis during follow-up but did not reach statistical significance in the primary analysis (**appendix p**

22).

The median CAD scores (by qXR v4) were highest among Ultra-positive controls (median 0.97 [IQR

0.86–0.99]) and lowest among negative controls (median 0.17 [IQR 0.06–0.36]). Among PWTS, those

dignosed at baseline and during follow-up had similar median CAD scores (median 0.84 [IQR 0.52–

0.97] versus 0.87 [IQR 0.70–0.89]); PWTS followed for ≥3 months without tuberculosis diagnosis had

lower CAD scores (median 0.30 [IQR 0.09–0.76]) than PWTS with tuberculosis diagnosis at baseline

(p=0.0001) or during follow-up (p=0.055). Among PWTS not diagnosed with tuberculosis, elevated CAD

scores occurred mainly in those with history of prior tuberculosis treatment (**Figure 4, appendix p 23**).

Baseline CXR interpretation by qXR v4 achieved an AUC of 0.77 (95% CI 0.69-0.86) for predicting

tuberculosis at baseline or during follow-up among PWTS. AUC did not change when tuberculosis was

defined microbiologically (AUC 0.77, 95% CI 0.68-0.86) (**Appendix p 24**). CAD score threshold of 0.5

had sensitivities of 77.4% (95% CI 65.6-86.0) and 74.5% (61.7-84.2), and specificities of 64.0% (50.1-

75.9) and 63.8% (49.5-76.0), using treatment-recommendation-based and microbiological definitions of

tuberculosis, respectively. (**Appendix p 25)**. The estimates of the AUC were higher among PWTS

without a prior history of tuberculosis treatment (AUC 0.84 [95% CI 0.76-0.92] versus 0.70 [0.47-0.92]

for treatment recommendation [p=0.24]; AUC 0.80 [95% CI 0.70-0.89] versus 0.75 [0.53-0.97] for

microbiological positivity [p=0.69]).

Of 62 PWTS recommended treatment at baseline or during follow-up who completed a CXR at baseline,

only four (6%) had very low qXR scores (<0.1); all their baseline X-rays were also interpreted as normal

by radiologists. One of them had a normal baseline chest CT but had untreated HIV and was started on

tuberculosis treatment by her HIV clinician. The remaining three participants, all of whom had culture-

confirmed tuberculosis, had subcentimeter nodules identifiable on their baseline chest CTs. Nearly all

PWTS diagnosed with tuberculosis at baseline or during follow-up (60 out of 63, 95%) had abnormal

chest CTs at baseline (**Table 2**), compared to 36% of PWTS who were not diagnosed.

Discussion

In this population-representative cohort of people with Ultra-trace-positive sputum in a high-burden

setting, the two-year risk of developing tuberculosis was high, even after a baseline evaluation that was

interpreted as excluding tuberculosis disease. Approximately one-third were diagnosed through
additional testing performed at enrollment, and of the remainder, the two-year cumulative hazard of
tuberculosis diagnosis was 0.33. Among PWTS not diagnosed with tuberculosis at baseline, those with
abnormal initial chest imaging had a particularly high risk of being diagnosed with tuberculosis during
follow-up, whereas baseline symptoms showed no prognostic value.

Our report highlights that individuals who receive trace results from tuberculosis screening are at
substantial risk of tuberculosis. While prior studies [3-5, 7] showed that 14% to 43% of screening
participants with trace-positive sputum were culture-positive, our results demonstrate that culture-
negative individuals with trace-positive screening results are still at significant risk of progressing to
tuberculosis diagnosis over time. In this study, 53% of PWTS were diagnosed with tuberculosis within
two years, and incompleteness of follow-up makes the true positive predictive value (PPV) even higher.
Importantly, the PPV may be even higher in populations with a greater underlying prevalence of
tuberculosis. For example, while this study used sputum Ultra as an initial test, most screening
programs utilize Ultra as a confirmatory test among individuals with abnormal chest X-ray and/or
symptoms.[3, 4] Since the prevalence of tuberculosis is higher among those who screen positive, the PPV
of the Ultra test will be also higher when used to confirm positive screening results.

When X-ray is used for screening, our results suggest that the screening step may also increase the
probability that those with trace results have or will soon develop tuberculosis, even if further
microbiological testing at the time of screening would be negative. Thus, our results support treatment
for tuberculosis disease in most individuals who receive trace sputum results during tuberculosis
screening, particularly when trace results are preceded by abnormal screening chest X-ray. The
appropriate treatment strategy for this form of paucibacillary tuberculosis is uncertain, as lower-burden
tuberculosis may be cured with shortened regimens.[15]

Our result that many PWTS may be culture negative yet at high risk to progress to more advanced
disease — while some others could remain without disease over two years — can be explained in the
context of the current understanding of the tuberculosis disease spectrum and natural history.
Tuberculosis has a dynamic disease course, and disease burden can fluctuate over time.[8, 10, 16] Some
culture-positive individuals may experience spontaneous improvement and become culture-negative.[9]
This immune-driven reduction in disease burden could leave nonviable *Mtb* that are detectable on
molecular tests even after the burden of viable bacteria becomes too small for culture to detect [17].
However, culture-negative individuals who once had enough mycobacterial burden to produce a
positive Ultra result, and who have not received sterilizing treatment, could be at high risk of
progressing to culture-positive disease The substantial proportion (nearly half) of PWTS with negative

baseline cultures who were nevertheless diagnosed with tuberculosis during this study also suggests
that the true specificity of Ultra in community screening contexts (which has already been shown[18] to be
higher than estimates in clinic-based populations) is even higher than previously estimated.

Our results also demonstrate the utility of chest imaging in interpreting Ultra trace results. More than
half of PWTS without tuberculosis at baseline had CXRs interpreted as normal by radiologists, and this
subset had a substantially lower risk of developing tuberculosis (cumulative hazard 0.05 at 2 years) —
potentially too low to justify empiric treatment for tuberculosis disease, although still above the risk in
contacts for whom preventive therapy is recommended.[19] It should be noted that radiologists
interpreting X-ray images in this study had access to paired CT images, and also that imaging results
informed clinical decision-making. Thus, the estimated hazard ratio likely overestimated the ability of X-
rays to discriminate early tuberculosis, particularly when the tuberculosis definition was not strictly
microbiological. However, X-ray scores by CAD software still demonstrated utility in identifying
individuals diagnosed with tuberculosis among PWTS, particularly among those without prior
tuberculosis.

This study has several limitations. Although we had an overall high rate of recruitment and retention,
there could have been selection bias. Our screening using Ultra may have preferentially selected
participants more capable of providing sputum. PWTS at higher risk of tuberculosis may have been
more likely to enroll into the study and complete follow-up. We did not induce sputum but accepted
suboptimal quality samples when necessary, which may have underestimated microbiological positivity.
Differential censoring of participants in the survival analysis may have biased our hazard estimates. In
particular, those started on treatment without microbiological confirmation were censored from the
analyses that used microbiological positivity as their outcome. Had those participants gone untreated,
they likely had a high risk of developing microbiological positivity later. Furthermore, if the highest-risk
individuals developed tuberculosis early in follow-up, their absence from the cohort during later time
periods may have biased our hazard ratio estimates.Under our primary definition of tuberculosis,
clinical diagnoses may have led to overestimation of diagnosis at baseline, biased the cohort being
followed toward lower-risk individuals, and/or overestimated two-year risk among that cohort. It is
reassuring that our estimates were similar under our secondary, microbiological definition, although
censoring individuals who started treatment and classifying false-positive microbiological results as
positives may have led to under- or overestimation of hazards, respectively. The limited number of
events in negative controls and PWTS with normal X-rays precluded adjustment for multiple covariates
and resulted in wide confidence intervals. Lastly, our study was conducted in a single city and

screening context, and results could differ in settings with different epidemiology of tuberculosis or
different healthcare and care-seeking practices.

In summary, we conducted community-based tuberculosis screening using sputum Ultra in Kampala,
and found that more than half of the individuals with a trace result were confirmed to have tuberculosis
within two years. Risk was elevated even among those not initially thought to have tuberculosis after
extensive baseline diagnostic procedures. Tuberculosis diagnosis during follow-up was strongly
associated with baseline chest imaging abnormalities but not with baseline symptoms. While further
research is needed to determine the most appropriate treatment strategy for these individuals, our
findings support tuberculosis treatment for most individuals with trace-positive screening results and
abnormal chest X-rays. For individuals with negative microbiology and normal chest X-rays,
individualized risk-benefit treatment decision making is needed, as their two-year risk of tuberculosis
may still exceed that of contacts who are recommended for tuberculosis preventive treatment.

Contributors

JS performed the data analysis and wrote the original draft of the manuscript. MN coordinated field data collection activities in Uganda. AN contributed to data management and data curation. PB and CV also contributed to data curation. JM, JA, RK, FK and MM enrolled participants and collected data in Uganda. CEK contributed to the laboratory processing of study samples. DWD contributed to the study's conception and critically revised the manuscript. AK contributed to the study's conception and supervised the data collection process in Uganda. EAK conceptualized the study, acquired funding and resources, supervised the data collection and development of the analytic plan, verified the underlying data, and critically revised the manuscript. All authors had full access to all the data in the study and accept responsibility for the decision to submit the manuscript for publication.

Data sharing

The deidentified dataset used for this study and a data dictionary will be available upon a reasonable request. Data sharing will be limited to non-commercial research use only. Requests should include a proposal outlining the intended use and methodology and will be subject to review and approval. Proposals can be directed to ekendall@jhmi.edu.

Declaration of interests

Authors report no conflicts of interest.

Acknowledgements

This work was supported by the National Institutes of Health (grant numbers R01HL153611 [to E. A. K.], R01HL138728 [to D. W. D.], T32AI007291 and K23AI185268 [to J.S.]). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Figure 1. Study procedures for evaluation and follow-up after a trace Ultra result during community-wide screening.
Community-based tuberculosis screening was conducted in Kampala, Uganda, from February 2021 to April 2024, using Ultra as the initial test. Participants with a trace-positive result were enrolled and underwent a detailed assessment, including symptom evaluation, additional microbiological testing (repeat sputum Ultra, two sets of sputum liquid and solid mycobacterial cultures, and urine LAM for people with HIV), chest X-ray, and chest CT. Those not initiated on treatment were followed at 1, 3, 6, 12, and 24 months, with repeat testing as outlined below. Sputum cultures at 6 and 24 months were offered to all participants who completed those visits after a November 2023 protocol revision. Both negative and positive controls underwent the same baseline evaluation. Negative controls were followed up to 24 months. One negative control participant with a trace result on repeat Xpert testing received similarly frequent follow-up as those with an initial trace result. All study follow-up ended in April 2025 (**Appendix p 13**).

*Negative and positive controls underwent the same baseline evaluation as participants with trace-positive sputum.

Figure 2. Recruitment and diagnostic outcomes of study participants with Ultra trace-positive sputum. The flow diagram illustrates the recruitment process and diagnostic outcomes of study participants. Most participants with trace-positive sputum were recruited from community-based tuberculosis screening conducted by the study team using Ultra as the initial test, and a minority of participants were recruited after undergoing similar symptom-neutral screening with Ultra through a national screening campaign. Of 498 participants (144, 144, and 210 with Ultra-positive, trace, and negative sputum results, respectively) evaluated for enrollment, 38 could not be contacted, 13 were ineligible, and 70 declined to participate (**appendix p 27**). Among participants with trace-positive sputum, there were 2 participants at baseline and 4 during follow-up with presumed false-positive microbiological results, for whom treatment was not recommended; these were not classified as "recommended for treatment" in this figure.

Table 1. Characteristics individuals screened for tuberculosis in community settings in Kampala, Uganda, according to initial sputum Ultra results and treatment recommendation.

	Positive Ultra (n=110)	Trace Ultra (n=121)[#]			Negative Ultra (n=139)
		Treatment recommended at baseline (n=45)	Treatment recommended during follow-up (n=19)	Treatment not recommended[#] (n=56)	
Age (years), median (IQR)[†]	35 (28, 42)	35 (24, 42)	32 (27, 39)	33.5 (25, 38)	32 (25, 39)
Female, n (%)[†]	26 (24%)	13 (29%)	7 (37%)	25 (45%)	60 (43%)
HIV positive, n (%)[†]	23 (21%)	9 (20%)	4 (21%)	6 (11%)	11 (8%)
HIV positive, not on antiretroviral therapy at enrollment, n (%)	4 (4%)	1 (2%)	2 (11%)	0 (0%)	1 (1%)
Household tuberculosis exposure within one year, n (%)	15 (14%)	7 (16%)	4 (21%)	7 (13%)	7 (5%)
Screened during contact investigation, n (%)	5 (5%)	2 (4%)	0 (0%)	3 (5%)	0 (0%)
Prior tuberculosis, n (%)	20 (18%)	4 (9%)	7 (37%)	12 (21%)	6 (4%)
Prior tuberculosis within 2 years, n (%)	13 (12%)	3 (7%)	3 (16%)	5 (9%)	3 (2%)
Current smoking, n (%)	36 (33%)	14 (31%)	7 (37%)	8 (14%)	16 (12%)
Underweight (body mass index <18.5 kg/m^2), n/N (%)	27/102 (25%)	17/45 (38%)	2/18 (11%)	4/46 (9%)	11/125 (9%)
Cough at screening[§], n/N (%)	67/94 (71%)	21/35 (60%)	3/9 (33%)	18/41 (44%)	35/120 (29%)
Cough at enrollment, n (%)	98 (89%)	37 (82%)	13 (68%)	37 (66%)	30 (22%)
Weeks of cough[‡], median (IQR)	5.5 (3, 16)	4 (2, 8)	2 (1, 6)	3 (1, 12)	2 (1, 4)
Cough severity on 0-100 scale,[‡] median (IQR)	50 (30, 70)	40 (20, 60)	30 (10, 50)	30 (20, 50)	28 (10, 30)
Any tuberculosis symptom*[§], n (%)	68/94 (72%)	22/35 (63%)	4/9 (44%)	20/41 (49%)	40/120 (33%)
Any tuberculosis symptom at enrollment**, n (%)	104 (95%)	40 (89%)	17 (89%)	47 (84%)	58 (42%)
Positive QuantiFERON, n/N (%)	59/67 (88%)	35/40 (88%)	12/15 (80%)	32/53 (60%)	51/106 (48%)
CRP ≥ 5.0 mg/L, n/N (%)	56/103 (54%)	19/44 (43%)	4/18 (22%)	13/56 (23%)	21/136 (15%)

[†] Matching constrained the age and sex of negative controls to be similar to, and HIV prevalence to be no greater than, that of PWTS as a whole.
[‡] Using visual analog scale,[20] if cough reported.
* any cough, fever, night sweats, or current weight loss at the time of screening
** any cough, fever, night sweats, or weight loss (5kg over 12 month) at the time of enrollment
[#] This excludes 8 participants who completed less than 3 months of follow-up.
[§] at the time of initial screening, prior to receiving Ultra result; asked of all individuals screening after June 2021
HIV = human immunodeficiency virus, IQR = interquartile range, CRP = C-reactive protein

Table 2. Baseline chest computed tomography characteristics of individuals screened for tuberculosis, according to initial sputum Ultra results and treatment recommendation.

	Positive Ultra (n=101)	Trace Ultra (n=117)			Negative Ultra (n=108)
		Diagnosed at baseline (n=44)	Diagnosed during follow-up (n=19)	Not diagnosed (n=53)	
Any abnormality	96 (95%)	41 (93%)	19 (100%)	19 (36%)	24 (22%)
Consolidation	55 (54%)	20 (45%)	4 (21%)	4 (8%)	3 (3%)
Ground glass opacity	32 (32%)	11 (25%)	3 (16%)	3 (6%)	4 (4%)
Nodule (≤3cm)	89 (88%)	34 (77%)	19 (100%)	14 (26%)	9 (8%)
Mass (>3cm)	3 (3%)	1 (2%)	0 (0%)	0 (0%)	0 (0%)
Septal thickening	77 (76%)	24 (55%)	12 (63%)	12 (23%)	5 (5%)
Bronchial or bronchovascular abnormality	79 (78%)	25 (57%)	10 (53%)	12 (23%)	7 (6%)
Cavitation	53 (52%)	10 (23%)	2 (11%)	2 (4%)	1 (1%)
Parenchymal fibrosis	61 (60%)	23 (52%)	11 (58%)	15 (28%)	7 (6%)
Volume loss	34 (34%)	11 (25%)	5 (26%)	7 (13%)	1 (1%)
Emphysematous changes	20 (20%)	9 (20%)	3 (16%)	9 (17%)	5 (5%)
Pleural thickening or fibrosis	20 (20%)	9 (20%)	3 (16%)	9 (15%)	5 (5%)
Mediastinal or hilar lymphadenopathy	14 (14%)	6 (14%)	3 (16%)	0 (0%)	0 (0%)
Cardiac abnormality	0 (0%)	0 (0%)	0 (0%)	1 (2%)	2 (2%)
Suggestive of active tuberculosis*[†]	83 (82%)	34 (77%)	12 (63%)	5 (9%)	4 (4%)
Suggestive of prior tuberculosis*	59 (58%)	26 (59%)	13 (68%)	13 (25%)	7 (6%)

*Rated by a majority of radiologists as at least somewhat suggestive of current active or prior tuberculosis.
[†] Of baseline CTs interpreted as suggestive of active tuberculosis, 52/ 83 among positive controls, 23/34 among PWTS diagnosed at baseline, 9/12 among PWTS diagnosed during follow-up, and 5/5 among negative controls were also rated as suggestive of prior tuberculosis.

Figure 3. **Cumulative cause-specific hazards of receiving a tuberculosis treatment recommendation (left) or developing a positive microbiological result for tuberculosis (right).** The upper panels (a, b) present the cumulative hazard of tuberculosis diagnosis during follow-up among participants not diagnosed at baseline, estimated using the negative log transformation of Kaplan-Meier survival curves and stratified by participants' initial Ultra results during community-wide tuberculosis screening. The lower panels (c, d) show results only for participants with initial trace-positive Ultra results, stratified by chest X-ray results at enrollment as interpreted by human readers. Shaded areas represent 95% confidence bands.

a) Treatment recommendation, by initial Ultra

b) Microbiological positivity, by initial Ultra

c) Treatment recommendation, by initial CXR

d) Microbiological positivity, by initial CXR

Figure 4. Distribution of CAD-interpreted baseline chest X-ray scores by initial sputum Ultra results and tuberculosis treatment recommendation. Results are shown for (a) all study participants and (b) participants without a prior history of tuberculosis, categorized into five groups: positive controls, PWTS diagnosed at baseline, PWTS diagnosed during follow-up, PWTS not diagnosed with TB, and negative controls. Curves represent the distribution of CAD scores based on kernel density estimates. Dots indicate median values, boxes show interquartile ranges, and whiskers extend to the upper and lower adjacent values for CAD scores in each group. The medians and interquartile ranges of CAD scores for each group are additionally described above each plot.

a) All participants

b) Participants without a prior history of tuberculosis

References

1.   World Health Organization. Global Tuberculosis Report 2024. Geneva, Switzerland: WHO; 2024.

2.   Burke RM, Nliwasa M, Feasey HRA, Chaisson LH, Golub JE, Naufal F, et al. Community-based active case-finding interventions for tuberculosis: a systematic review. Lancet Public Health. 2021;6(5):e283-e99.

3.   Moyo S, Ismail F, Van der Walt M, Ismail N, Mkhondo N, Dlamini S, et al. Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey. Lancet Infect Dis. 2022;22(8):1172-80.

4.   Matji R, Maama L, Roscigno G, Lerotholi M, Agonafir M, Sekibira R, et al. Policy and programmatic directions for the Lesotho tuberculosis programme: Findings of the national tuberculosis prevalence survey, 2019. PLoS One. 2023;18(3):e0273245.

5.   Sung J, Nantale M, Nalutaaya A, Biché P, Mukiibi J, Kamoga CE, et al. Evidence for Tuberculosis in Individuals With Xpert Ultra "Trace" Sputum During Screening of High-Burden Communities. Clin Infect Dis. 2024;78(3):723-9.

6.   Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017;8(4).

7.   Floyd S, Klinkenberg E, de Haas P, Kosloff B, Gachie T, Dodd PJ, et al. Optimising Xpert-Ultra and culture testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South Africa. BMJ Open. 2022;12(6):e058195.

8.   Coussens AK, Zaidi SMA, Allwood BW, Dewan PK, Gray G, Kohli M, et al. Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise. Lancet Respir Med. 2024;12(6):484-98.

9.   Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Respir Med. 2023;11(4):367-79.

10.   Richards AS, Sossen B, Emery JC, Horton KC, Heinsohn T, Frascella B, et al. Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study. Lancet Glob Health. 2023;11(5):e684-e92.

11.   Bamuloba M, editor Lessons from the CAST TB/Leprosy campaign. 2023 PEPFAR Uganda Science Summit; 2023; Kampala, Uganda.

12.   Galiwango RM, Musoke R, Lubyayi L, Ssekubugu R, Kalibbala S, Ssekweyama V, et al. Evaluation of current rapid HIV test algorithms in Rakai, Uganda. J Virol Methods. 2013;192(1-2):25-7.

13.   Therneau T. A package for survival analysis in S. R package version. 2015;2(7):2014.

14.   Dinno A. Nonparametric pairwise multiple comparisons in independent groups using Dunn's test. Stata Journal. 2015;15(1):292-300.

15.   Gray AT, Macpherson L, Carlin F, Sossen B, Richards AS, Kik SV, et al. Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review and meta-analysis. PLoS One. 2023;18(11):e0293535.

16.   Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev. 2018;31(4).

17.	Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, et al. False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. J Clin Microbiol. 2018;56(3).

18.	Veeken LD, Schwalb A, Horton KC, Koesoemadinata RC, Alisjahbana B, van Crevel R, et al. Mind the clinic-community gap: how concerned should we be about false positive test results in mass tuberculosis screening? J Infect Dis. 2025.

19.	World Health Organization. WHO operational handbook on tuberculosis. Module 1: prevention-tuberculosis preventive treatment: World Health Organization; 2024.

20.	Lee KK, Matos S, Evans DH, White P, Pavord ID, Birring SS. A longitudinal assessment of acute cough. Am J Respir Crit Care Med. 2013;187(9):991-7.